Annamycin

CAS : 92689-49-1

Ref. 3D-FA150912

Informations sur le produit

• Nom: Annamycin
• Synonymes: (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,6-dideoxy-2-iodo-alpha-L-mannopyranoside, (7S,9S)-7-[(2,6-Dideoxy-2-iodo-α-<span class="text-smallcaps">L</span>-mannopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-5,12-naphthacenedione, (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione, 5,12-Naphthacenedione, 7-[(2,6-dideoxy-2-iodo-α-<span class="text-smallcaps">L</span>-mannopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-, (7S,9S)-, 5,12-Naphthacenedione, 7-[(2,6-dideoxy-2-iodo-α-<span class="text-smallcaps">L</span>-mannopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S,9S)-

Description

Annamycin is a pyrimidine compound that exhibits cytotoxic activity against cancer cells, including CD-1 mice bearing an autoimmune disease. It is also an anti-infective agent used to treat bacterial and fungal infections. Annamycin binds to the Mcl-1 protein and inhibits its ability to regulate apoptosis by binding to the Bcr-Abl kinase. This binding blocks the pro-apoptotic effects of Bcr-Abl, leading to cell death. A monoclonal antibody is being developed for use with annamycin which will increase the drug's specificity for cancer cells, thereby reducing side effects. This drug has a phase transition temperature of -20°C and fluorescence spectrometry at 520 nm with a molar extinction coefficient of 140000 M cm.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 640.37 g/mol
• Formule: C₂₆H₂₅IO₁₁
• Degré de pureté: Min. 95%